STADA
German pharmaceutical company focused on consumer healthcare, generic medicines and specialty pharmaceuticals.
Last updated October 6, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
STADA Arzneimittel AG is a German pharmaceutical company headquartered in Bad Vilbel. Its business is organized around three principal areas: consumer healthcare, generic medicines and specialty pharmaceuticals. The company supplies prescription and non-prescription products through pharmacies, wholesalers, hospitals and other healthcare channels, with operations and sales extending well beyond Germany. STADA traces its origins to 1895, when it was established in Dresden as a cooperative organization of pharmacists. The name was derived from “Standardarzneimittel Deutscher Apotheker,” referring to standardized medicines for German pharmacists. After the Second World War, the organization moved first to Essen and Tübingen before settling in Bad Vilbel in 1956. It began trading publicly in 1970, initially using registered shares whose transfer was restricted to pharmacists. In 1975, STADA entered the generic-drug market, which later became one of the central pillars of its business model. From the late 1990s through the 2010s, STADA expanded internationally through subsidiaries, acquisitions and partnerships. The company strengthened its generic-drug presence in Spain, Italy, the United Kingdom, Portugal, Russia and other markets, while also adding consumer-health and specialty products. Important transactions included the acquisition of American generic supplier MOVA Laboratories, Spanish company Bayvit, a controlling interest in Russian pharmaceutical group Nizhpharm, and UK over-the-counter manufacturer Thornton & Ross. The group also developed positions in nutritional supplements and dermatological products. STADA’s branded consumer-health portfolio has included products such as Grippostad-C cold medicine, Silomat cough remedies, Ladival sun protection products, lactulose and paracetamol or acetaminophen products sold under STADA-related brands. Its generic business supplies medicines whose active ingredients are available across a range of therapeutic areas, while its specialty-pharma activities address selected products and indications requiring more focused commercial or medical support. The company became the subject of an intense takeover process in 2017. After several possible bidders showed interest, Bain Capital and Cinven ultimately agreed to acquire STADA through the Nidda Healthcare structure. Their first tender offer did not meet the required acceptance threshold, but a subsequent offer succeeded in August 2017. STADA subsequently operated as a privately held pharmaceutical group rather than as a broadly publicly traded German company. STADA has also participated in charitable and sponsorship initiatives, including support for dolphin aid e.V. and a Romanian children’s village in Timișoara. Its commercial positioning combines the scale and cost discipline of a generic-drug manufacturer with the consumer recognition of over-the-counter brands and the higher specialization of selected prescription products. In 2022, the company reported revenue of €3.79 billion.
History
STADA traces its origins to 1895 in Germany. The organization began within the German pharmacy sector and gradually developed into a pharmaceutical business serving the needs of pharmacists, healthcare professionals, and patients. Its early identity was associated with cooperation and the supply of medicines through the pharmacy channel. Over the course of the twentieth century, STADA expanded its pharmaceutical activities and established a broader commercial presence. As generic medicines became increasingly important to healthcare systems, the company developed a substantial position in the supply of off-patent medicines. Generic products enabled STADA to compete through manufacturing capability, regulatory expertise, portfolio breadth, and distribution rather than relying primarily on discovery of new molecular entities. The company later complemented generics with consumer healthcare and specialty pharmaceuticals. Consumer healthcare gave STADA access to self-care categories in which established brands, pharmacy relationships, and consumer recognition are important. Specialty pharmaceuticals added products requiring more specialized development, regulatory management, or commercial support. The resulting three-pillar structure—consumer healthcare, generics, and specialty pharma—became the central description of the group's business model. STADA also internationalized its operations. It built and acquired businesses in multiple markets, while retaining a strong base in Germany and Europe. Its international portfolio included products marketed under different local and global brand names, reflecting the fragmented nature of pharmaceutical regulation and healthcare distribution. This approach allowed the company to combine global scale with market-specific portfolios. For a significant period, STADA operated as a publicly traded German pharmaceutical company. The group became the subject of a takeover process in 2017, when Bain Capital and Cinven acquired the company. Following the transaction, STADA was delisted and continued as a privately owned pharmaceutical group. This marked a major change in ownership and capital-market status, but not an end to the operating business. In its current form, STADA presents itself as an international healthcare company focused on consumer healthcare, generics, and specialty pharmaceuticals. Its business serves both professional healthcare channels and consumers. The company is therefore distinct from a single consumer product brand: STADA is a corporate pharmaceutical group with a portfolio of prescription medicines, non-prescription products, and specialty therapies distributed across numerous markets.
Products and positioning
An international pharmaceutical and healthcare platform combining consumer healthcare, generics, and specialty pharmaceuticals, with a strong European operating base.
Prescription pharmaceuticals
Generic medicines
STADA's generic-medicines business supplies pharmaceutical products based on active ingredients whose exclusivity protections have expired. These medicines are intended to provide established therapies at more accessible prices and are distributed through pharmacies, healthcare providers, hospitals, and national reimbursement systems. The portfolio is market-specific because product approvals, naming, packaging, and reimbursement arrangements differ by country.
Over-the-counter and self-care products
Consumer healthcare
The consumer-healthcare portfolio includes non-prescription medicines and other self-care products intended for common health needs. Products may be sold through pharmacies, retailers, and other consumer channels, with brand recognition and local market execution playing an important role. STADA operates both internationally recognized and market-specific consumer-health brands within this business area.
Specialty medicines
Specialty pharmaceuticals
STADA's specialty-pharmaceuticals pillar comprises medicines with more differentiated clinical, regulatory, or commercial characteristics than conventional generics. These products can require specialized medical communication, focused distribution, or particular expertise in development and market access. The pillar broadens STADA's portfolio beyond high-volume off-patent medicines and everyday self-care products.
Brand decisions
2017
Acceptance of the Bain Capital and Cinven acquisitionM&ABackground
STADA was a publicly traded pharmaceutical group when it became the target of an acquisition by Bain Capital and Cinven.
Action taken
The acquisition was completed and STADA was subsequently taken private and delisted.
Aftermath
STADA continued operating as a privately owned pharmaceutical company, while its historical public-market ticker ceased to represent a current listing.
Recent events
- 2020
Peter Goldschmidt appointed chief executive officer[2]
Leadership change
STADA appointed Peter Goldschmidt as chief executive officer, succeeding Claudio Alocci.
- 2018
Leadership transition follows the acquisition[3]
Leadership change
Peter Goldschmidt was appointed to succeed Claudio Albrecht as chief executive, while Albrecht remained associated with the company in a non-executive capacity.
- 2017
STADA acquired and taken private by Bain Capital and Cinven[1]
M&A
STADA was acquired by investment firms Bain Capital and Cinven and subsequently ceased to be a publicly listed company.
- 2017
Bain Capital and Cinven launch a takeover bid for STADA[3]
M&A
The private-equity consortium offered cash consideration for STADA shares in a transaction valuing the company at approximately €5.3 billion, alongside a dividend component.
- 2017
Initial Bain-Cinven tender offer fails to reach the acceptance threshold[3]
M&A
The first takeover attempt received 65.52% of shares, below the 67.5% minimum required under the offer terms.
- 2017
Bain Capital and Cinven complete the acquisition of STADA[3]
M&A
A subsequent offer enabled the consortium to acquire STADA and move the company into private ownership through the Nidda Healthcare structure.
- 2017
Bain Capital and Cinven complete acquisition of STADA[2]
M&A
An investor consortium led by Bain Capital and Cinven completed the acquisition of STADA after a contested takeover process, taking the pharmaceutical company private.
Sources5 sources
- 1STADA Global official websitestada.com
- 2Peter Goldschmidt被任命为首席执行官stada.com
- 3收购后领导层过渡en.wikipedia.org
- 4STADA Corp Partners with No Kid Hungry in the Fight Against Childhood Hungerprnewswire.com
- 5STADA Romania announces an investment of 48.3 million euros in a new factory - Business Reviewbusiness-review.eu
Cite this profile: Cite the canonical profile. /brand-wiki/stada · Editorial policy · How profiles are compiled